Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery: The VICTORY Trial
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
HYPOTHESES
- Rosiglitazone in diabetic patients with previous coronary bypass surgery may prevent or
slow the progression of atherosclerosis in SVGs and native coronary arteries.
- Rosiglitazone has favorable effects on adipose tissue distribution variables as well as
on thrombosis, pro-inflammatory, and lipid profiles in diabetic patients after coronary
bypass artery surgery.
- Rosiglitazone therapy influences favorably metabolism and clinical outcomes in diabetic
patients after coronary artery bypass surgery.
OBJECTIVES
- PRIMARY To assess the efficacy of rosiglitazone to reduce atherosclerosis progression in
vein grafts in diabetic patients after coronary bypass surgery by using IVUS imaging
after a 12 mo follow-up.
- SECONDARY
- To prospectively compare the secondary IVUS endpoints.
- To prospectively compare the angiographic endpoints.
- To prospectively compare the metabolic risk factor endpoints.
- To prospectively compare the body composition and distribution endpoints.
- To prospectively compare the clinical outcomes of rosiglitazone versus standard
care using composite endpoints.